What it's for (Indications)
- Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer (mCRC) as determined by an FDA-approved test.
- It can be used either in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment or as a single agent in patients who have failed irinotecan-, oxaliplatin-, and fluoropyrimidine-based therapy.
- Furthermore, cetuximab is indicated for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
- For locally advanced SCCHN, it is used in combination with radiation therapy.
- For recurrent locoregional disease or metastatic SCCHN, it is administered in combination with platinum-based chemotherapy and 5-fluorouracil.
- These indications highlight its role in targeted cancer therapy, addressing specific molecular profiles and disease stages.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended initial dose of cetuximab is 400 mg/m² administered as a 120-minute intravenous (IV) infusion. This loading dose is crucial for rapidly achieving therapeutic serum concentrations. Subsequent weekly doses are maintained at 250 mg/m², administered over 60 minutes. To mitigate the risk of infusion-related reactions, premedication with an H1 antagonist (e.g., diphenhydramine) is generally recommended approximately 30-60 minutes prior to the first infusion and all subsequent infusions. Dosage modifications, including dose interruption or reduction, may be necessary based on the severity and persistence of adverse events, particularly dermatologic toxicities and infusion reactions. Close monitoring of patients during and after administration is essential to ensure safety and optimize therapeutic outcomes, adjusting the regimen as clinically indicated. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with cetuximab therapy include a range of dermatologic toxicities, such as acneiform rash, pruritus, dry skin, skin fissures, and paronychia, which can affect a significant majority of patients.
- Infusion-related reactions (IRRs) are also prevalent, presenting with symptoms from mild fever and chills to severe anaphylactic responses.
- Other frequently reported side effects encompass fatigue, nausea, vomiting, diarrhea, constipation, stomatitis (mouth sores), and headache.
- Electrolyte abnormalities, particularly hypomagnesemia, are a recognized risk that often necessitates supplementation and careful monitoring.
- More serious, though less common, adverse events include interstitial lung disease, cardiac arrest (especially when used concurrently with radiation therapy for SCCHN), and severe infections, underscoring the need for comprehensive patient surveillance and proactive management strategies.
Serious Warnings
- Black Box Warning: **WARNING: INFUSION REACTIONS AND CARDIOPULMONARY ARREST** **Infusion Reactions:** Serious and sometimes fatal infusion reactions have been reported with cetuximab. Approximately 2.5% of patients in clinical trials experienced severe (Grade 3 or 4) infusion reactions. These reactions are characterized by a rapid onset of symptoms such as airway obstruction (bronchospasm, stridor, hoarseness), hypotension, shock, loss of consciousness, and/or myocardial infarction. While severe reactions typically occur during or within 1 hour following the first cetuximab infusion, they can also occur with subsequent infusions. Severe reactions necessitate immediate and permanent discontinuation of cetuximab, along with aggressive symptomatic treatment. Premedication with an H1 antagonist (e.g., diphenhydramine) is recommended prior to each infusion to mitigate this risk. **Cardiopulmonary Arrest:** Cardiopulmonary arrest or sudden death occurred in 3% of patients with squamous cell carcinoma of the head and neck treated with radiation therapy and cetuximab in clinical studies. This risk appears to be elevated when cetuximab is combined with radiation therapy. Due to this potential for serious cardiovascular events, patients should be closely monitored for signs and symptoms of cardiopulmonary compromise, particularly during and after cetuximab administration, especially in the context of combined modality therapy for head and neck cancer.
- Patients receiving cetuximab are at significant risk for developing severe infusion-related reactions, which can be fatal.
- These reactions often occur during or within an hour following the first infusion but can also manifest with subsequent doses, presenting as bronchospasm, stridor, hoarseness, urticaria, hypotension, and chest pain.
- Additionally, severe dermatologic toxicities, including acneiform rash, skin desquamation, and rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis, can lead to serious complications and may necessitate dose interruption or discontinuation.
- Pulmonary toxicity, including interstitial lung disease, has been reported.
- Electrolyte disturbances, particularly hypomagnesemia, can be severe and require careful monitoring and aggressive supplementation.
- There is also an increased risk of cardiac arrest or sudden death, particularly when cetuximab is administered concurrently with radiation therapy for squamous cell carcinoma of the head and neck.
- Furthermore, cetuximab can cause fetal harm when administered to a pregnant woman, classified as Pregnancy Category C, and therefore, women of childbearing potential should use effective contraception during and for 2 months after treatment.
How it Works (Mechanism of Action)
Cetuximab is a chimeric (mouse/human) monoclonal antibody of the immunoglobulin G1 (IgG1) subtype that specifically targets and binds with high affinity to the extracellular domain of the epidermal growth factor receptor (EGFR). By binding to EGFR, cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other endogenous ligands to the receptor. This inhibition effectively blocks receptor dimerization, autophosphorylation, and the subsequent activation of downstream intracellular signaling pathways, notably the Ras/Raf/MEK/ERK and PI3K/Akt pathways. Consequently, EGFR-mediated cellular processes such as cell growth, proliferation, survival, angiogenesis, and metastasis are suppressed. The drug also mediates antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells, contributing to its multifaceted antitumor effects. This precise mechanism allows for targeted therapy, interfering with critical pathways involved in cancer progression.
Commercial Brands (Alternatives)
No other brands found for this formula.